Clover Health Investments, CORP /DE

Clover Health disclosed a cybersecurity incident on July 4, 2026, involving unauthorized access to employee accounts, with an ongoing investigation into data impact.

Clover Health Investments, Corp. successfully concluded its 2026 Annual Meeting with shareholders electing directors and ratifying its accounting firm.

Clover Health Investments, Corp. announced a favorable court ruling and subsequent recalculation of its 2026 Medicare Star Rating to 4.5 stars, impacting over 97% of its members.

Clover Health released supplemental Q&A addressing Q1 2026 performance, business outlook, and long-term strategy, emphasizing Clover Assistant's impact on medical costs and margin expansion.

Clover Health Investments, Corp. announced the departure of CFO Peter Kuipers and the appointment of Clay Thornton as Interim CFO, while reiterating its full fiscal year 2026 financial guidance.

Clover Health outlines its strategy for achieving full-year GAAP Net Income profitability in 2026, emphasizing cohort maturation, Clover Assistant engagement, and operating leverage.

Clover Health Investments, Corp. announced a significant turnaround in its Q1 2026 financial performance, reporting a net income of $27.3 million compared to a net loss in the prior year.

Clover Health reported a significantly wider net loss in Q3 2025 despite revenue growth, alongside a critical downgrade of its primary Medicare Advantage PPO plans to 3.5 Stars for 2026.

Clover Health Investments, Corp. reported a net loss for Q2 2025, driven by a significant increase in medical claims incurred despite strong revenue and membership growth.

Clover Health's Q1 2025 results show revenue growth driven by increased membership in its Medicare Advantage plans.

Clover Health's Q3 2024 results show a decrease in net loss and improvements in key financial metrics, driven by growth in premiums and reduced operating expenses.

Clover Health's Q2 2024 results show a revenue increase but also highlight ongoing challenges with medical claims and restructuring costs.

Clover Health reported a net loss of $85.5 million for 2025, despite significant revenue growth and increased Medicare Advantage membership, as it continues to invest in its AI-powered Clover Assistant platform and expand its Counterpart Health subsidiary.

Clover Health's 2024 10-K filing highlights membership growth, strategic shifts towards PPO plans and SaaS offerings, and ongoing efforts to improve financial performance and regulatory compliance.

Clover Health Investments Corp. released its 2023 annual report, detailing financial performance and the strategic decision to exit the ACO REACH program.

Karen Soares, Chief Legal Officer of Clover Health Investments, Corp. /De, sold 51,700 shares of common stock on July 20, 2026 for $4.51 per share.

Jamie L. Reynoso, CEO, Medicare Advantage of Clover Health Investments, Corp. /De, sold 4,839 shares of common stock on July 17, 2026 for $4.53 per share.

Andrew Toy, Chief Executive Officer and a Director of Clover Health Investments, Corp. /De, sold 62,711 shares of common stock on July 15, 2026 for $4.67 per share.

Conrad Wai, CEO, Counterpart Health of Clover Health Investments, Corp. /De, sold 24,215 shares of common stock on July 15, 2026 for $4.67 per share.

Jamie L. Reynoso, CEO, Medicare Advantage of Clover Health Investments, Corp. /De, sold 13,119 shares of common stock on July 15, 2026 for $4.67 per share.

Karen Soares, Chief Legal Officer of Clover Health Investments, Corp. /De, sold 10,519 shares of common stock on July 15, 2026 for $4.67 per share.

Clover Health Investments, Corp. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, detailing director elections, executive compensation, and auditor ratification.

Clover Health Investments Corp. is holding its annual stockholder meeting on June 10, 2025, and has provided details on how stockholders can vote on key proposals.

Clover Health Investments will hold its annual stockholder meeting virtually on June 10, 2025, to vote on director elections, executive compensation, and auditor ratification.

Clover Health Investments Corp. announces its 2024 Annual Meeting to be held virtually on June 10, 2024, outlining key proposals for stockholder voting including the election of directors, executive compensation, and auditor ratification.

Clover Health Investments will hold its 2024 annual meeting of stockholders virtually on June 10, 2024, to vote on director elections, executive compensation, and the ratification of its accounting firm.

The Vanguard Group has reported a 0% beneficial ownership in Clover Health Investments Corp following an internal realignment.

The Vanguard Group has reported a passive beneficial ownership of 5.82% in Clover Health Investments Corp, holding over 24 million shares of common stock.

BlackRock, Inc. has reported a 7.2% passive beneficial ownership stake in Clover Health Investments Corp. Class A Common Stock, totaling 29,813,646 shares.